The hand sanitizer products, called Zylast, claim to be effective against infection by pathogens including the norovirus, rhinovirus, rotavirus, flu virus and Ebola virus, despite a lack of evidence supporting the claim and the fact that the FDA has not approved the product.
The court said the hand sanitizer products are considered to be “unapproved new drugs” and that the company, Innovative BioDefense, was violating the Federal Food, Drug and Cosmetic Act by selling it.
The court ruled that the company, based in Lake Forest, Calif., can’t sell the Zylast hand sanitizer products until it gets FDA approval or removes disease-specific claims from the products’ labeling.
Read the full news release here.
More articles on supply chain:
ICE working with Amazon, Pfizer to keep fake COVID-19 supplies out of US
FDA tightens standards for COVID-19 antibody tests
LabCorp furloughs employees
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
